Episode Details

McDonald's just named GLP-1 users a core menu audience with an $8B commitment — and glucosamine, one of Europe's top joint supplements, is now linked to faster Alzheimer's progression. Both stories demand action from supplement and functional food marketers today.

In this episode:

• A large health-record analysis found glucosamine users face a 25% higher likelihood of progressing from mild cognitive impairment to full dementia, putting serious reputational pressure on one of Europe's best-selling joint supplements.
• McDonald's has announced an $8B-plus strategic investment that explicitly redesigns its menu for GLP-1 drug users seeking smaller portions and higher protein density — the first global fast food chain to publicly name Ozempic-era consumers as a core audience.
• A topical senolytic compound cleared aged skin cells in older mice, dramatically accelerating wound healing and reversing biological ageing markers — adding scientific momentum to the quercetin and fisetin ingredient category already in European longevity supplement pipelines.
• Impossible Foods has entered UK retail grocery for the first time with a new plant-based protein range, making a high-stakes bet on health-positioned products in one of Europe's most competitive grocery markets amid wider category decline.

The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day.

Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us.

Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily